

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


## **Single Technology Appraisal**

# Guselkumab for previously treated moderately to severely active Crohn's disease ID6238

## **Provisional Stakeholder List**

Consultees	Commentators (no right to submit or appeal)
Company	General
Janssen (guselkumab)	All Wales Therapeutics and Toxicology
Patient/carer groups	<ul><li>Centre</li><li>Allied Health Professionals Federation</li></ul>
Bladder and Bowel Community	Board of Community Health Councils in
Bowel Cancer UK	Wales
Colostomy UK	<ul> <li>British National Formulary</li> </ul>
Crohn's and Colitis UK	Care Quality Commission
GUTS UK	Department of Health, Social Services     Department of Health, Social Services
IA: Ileostomy and Internal Pouch     Association	<ul><li>and Public Safety for Northern Ireland</li><li>Healthcare Improvement Scotland</li></ul>
IBDrelief	<ul> <li>Medicines and Healthcare products</li> </ul>
South Asian Health Foundation	Regulatory Agency
Specialised Healthcare Alliance	National Association of Primary Care
·	National Pharmacy Association
Healthcare professional groups	NHS Confederation
Association of Coloproctology of Great      Dritain and Iroland	Scottish Medicines Consortium
Britain and Ireland     Association of Surgeons of Great	Welsh Government     Welsh Health Specialized Services
Britain and Ireland	<ul> <li>Welsh Health Specialised Services Committee</li> </ul>
British Geriatrics Society	
British Society of Gastroenterology	Possible comparator companies
Primary Care Society for	AbbVie (adalimumab, risankizumab,
Gastroenterology	upadacitinib)
Royal College of Anaesthetists     Royal College of Conoral Prostitioners	Amgen (adalimumab)     Piagan Rissimilara (adalimumab
<ul><li>Royal College of General Practitioners</li><li>Royal College of Nursing</li></ul>	<ul> <li>Biogen - Biosimilars (adalimumab, infliximab)</li> </ul>
Royal College of National     Royal College of Pathologists	Celltrion Healthcare UK (adalimumab,
Royal College of Physicians	infliximab)
Royal College of Surgeons of England	Fresenius Kabi (adalimumab)
Royal Pharmaceutical Society	Janssen (ustekinumab)
Royal Society of Medicine	Merck Sharp & Dohme (infliximab)  Diagram (inflixing la)
UK Clinical Pharmacy Association	Pfizer (infliximab)     Sendez (adelimumab infliximab)
<u>Others</u>	<ul><li>Sandoz (adalimumab, infliximab)</li><li>Takeda UK (vedolizumab)</li></ul>
Department of Health and Social Care	- Tancua Ort (Vouolizuillab)

Provisional stakeholder list for the evaluation of guselkumab for previously treated moderately to severely active Crohn's disease ID6238



Consultees	Commentators (no right to submit or appeal)
NHS England	<ul> <li>Relevant research groups</li> <li>Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Group</li> <li>Genomics England</li> <li>MRC Clinical Trials Unit</li> <li>National Institute for Health Research</li> <li>Associated Public Health groups</li> <li>Public Health Wales</li> <li>UK Health Security Agency</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

#### **Definitions:**

### **Consultees**

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

#### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

Provisional stakeholder list for the evaluation of guselkumab for previously treated moderately to severely active Crohn's disease ID6238

Issue date: July 2024